Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 24/06/21 → 23/06/26 |
Keywords
- phase 3 study
- treatment safety
- treatment effficacy
- Myelofibrosis
Clinical Trial Phase
- Phase III (a & b)
A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI 0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients
- Yeh, Paul (Primary Chief Investigator (PCI))
Project: Research